Welcome to our dedicated page for Purple Biotech news (Ticker: PPBT), a resource for investors and traders seeking the latest updates and insights on Purple Biotech stock.
Purple Biotech Ltd. (PPBT) generates frequent news as a clinical-stage oncology company developing therapies that, according to its own reports, target tumor immune evasion and drug resistance. Investors and observers following PPBT news can track updates on its CAPTN-3 tri-specific antibody platform, the CEACAM1-blocking antibody CM24, and the dual IRS1/2 and STAT3 inhibitor NT219, as well as financing and listing developments.
Recent press releases highlight CAPTN-3 as a key source of news. The company has announced manufacturing milestones for IM1240, the first tri-specific antibody from the platform targeting 5T4, CD3 and NKG2A, including achievement of a commercially viable yield. Additional updates describe non-human primate toxicology data for IM1240, with Purple Biotech reporting an expanded therapeutic window compared with a non-capped comparator and a pharmacokinetic profile characterized by increased systemic exposure and prolonged half-life in that study.
News flow also covers preclinical data presentations at scientific meetings such as the ESMO Immuno-Oncology Congress and other conferences. These releases describe anti-tumor activity of IM1240 and IM1305 in models resistant to prior PD-1 therapy, transcriptomic analyses supporting the inclusion of an NKG2A arm, and ex vivo results in patient-derived tumor biopsies. Such items provide context on how the company positions CAPTN-3 within immuno-oncology research.
Beyond CAPTN-3, Purple Biotech issues updates on CM24 Phase 2 data in pancreatic ductal adenocarcinoma and on NT219, including an intention to grant a European patent for NT219 combination regimens and progress of a Phase 2 study in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Financial and corporate news includes quarterly results, public offerings of American Depositary Shares and warrants, at-the-market offering agreements, and Nasdaq minimum bid price notifications.
Readers who monitor PPBT news can use this page to follow scientific milestones, regulatory and clinical progress, capital-raising transactions, and listing-related announcements directly sourced from company press releases and SEC-furnished documents.
Purple Biotech (PPBT) announced significant advancements in its anti-cancer therapies and financial results for 2020. Key highlights include the completion of patient recruitment for the NT219 clinical trial and imminent Phase 1b/2 studies for CM24. The company raised $68.5 million in 2020, ending with $60.8 million in cash, sufficient to support operations until 2024. Despite increased R&D expenses leading to a higher operating loss of $12.6 million, cash resources appear robust, supporting ongoing clinical initiatives aimed at improving cancer treatment outcomes.